Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 5th:Corcept Therapeutics Incorporated (CORT) : This drugmaker for severe endocrinologic, oncologic, metabolic, and neurologic disorders has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 13.6% over the last 60 days.Corcept’s shares gained 46.4% over the last three months compared with the S&P 500’s advance of 9.1%. The company possesses a Mome ...

Have you been paying attention to shares of Corcept Therapeutics (CORT) ? Shares have been on the move with the stock up 12.1% over the past month. The stock hit a new 52-week high of $51.32 in the previous session. Corcept Therapeutics has gained 54.1% since the start of the year compared to the 3.1% move for the Zacks Medical sector and the -4.2% return for the Zacks Medical - Drugs industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't m ...

Shares of Corcept Therapeutics (CORT) have gained 4.8% over the past four weeks to close the last trading session at $47.62, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $74.60 indicates a potential upside of 56.7%.The mean estimate comprises five short-term price targets with a standard deviation of $5.18. While the lowest estimate of $67 indicates a 40.7% increase from the ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

Investors might want to bet on Corcept Therapeutics (CORT) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.The upward trend in estimate revisions for this drug developer reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation be ...

Corcept Therapeutics Incorporated (CORT) reported third-quarter 2024 earnings of 41 cents per share, which significantly beat the Zacks Consensus Estimate of 27 cents. The company had reported earnings of 28 cents per share in the year-ago quarter.Revenues in the third quarter increased 48% year over year to $182.5 million. The figure also beat the Zacks Consensus Estimate of $172 million. The top line solely comprises product sales of Cushing’s syndrome drug, Korlym.Corcept's shares were down 10.5% in afte ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joe Belanoff - Chief Executive Officer Conference Call Participants David Amsellem - Piper Sandler Matt Kaplan - Ladenburg Swayampakula Ramakanth - H. C. Wainwright Joon Lee - Truist Operator Good day and thank you for standing by. Welcome to the Corcept Therapeutics Conference Call. At this time, all p ...

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.28 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 51.85%. A quarter ago, it was expected that this drug developer would post earnings of $0.23 per share when it actually produced earnings of $0.32, delivering a surprise of 39.13%. Over the last four quarters ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 ________________ ...

EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS, POSITIVE RESULTS FROM PHASE 3 GRADIENT TRIAL IN PATIENTS WITH CUSHING'S SYNDROME AND PROVIDES CORPORATE UPDATE • Revenue of $182.5 million, a 48 percent increase over the same period in 2023 • Increase in 2024 revenue guidance to $675 – $700 million, from $640 – $670 million • Net income per common share of $0.41 (diluted), compared to $0.28 in third quarter 2023 • Cash and investments of $547.6 million as of September 30, 2024 • R ...